|
Video: What is a Stock Split?
|
|
Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need. According to our Intellia Therapeutics stock split history records, Intellia Therapeutics has had 0 splits. | |
|
Intellia Therapeutics (NTLA) has 0 splits in our Intellia Therapeutics stock split history database.
Looking at the Intellia Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Intellia Therapeutics shares, starting with a $10,000 purchase of NTLA, presented on a split-history-adjusted basis factoring in the complete Intellia Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/09/2016 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$24.00 |
|
End price/share: |
$21.81 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-9.13% |
|
Average Annual Total Return: |
-1.20% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,085.68 |
|
Years: |
7.94 |
|
|
|
|
|